NL-OMON25145招募中4 期
A multicenter, open-label, non-inferiority, randomized controlled trial comparing mechanochemical endovenous ablation using Flebogrif with endovenous laser ablation in the treatment of primary great saphenous vein incompetence
oordwest Ziekenhuisgroep0 个研究点目标入组 320 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 320
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Leeftijd 18-80 jaar |
排除标准
- •- C6 varices |
研究者
相似试验
招募中
不适用
A multicenter, open-label, non-inferiority, randomized controlled trial comparing mechanochemical endovenous ablation using Flebogrif with endovenous laser ablation in the treatment of primary great saphenous vein incompetence.spider veinsVaricose veins10057165NL-OMON54246oordwest Ziekenhuisgroep310
已完成
3 期
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemiablood cancer10024324leukemiaNL-OMON54575Acerta Pharma BV60
进行中（未招募）
1 期
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic LeukemiaHigh Risk Chronic Lymphocytic LeukemiaMedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2014-005530-64-BEAcerta Pharma B.V.500
进行中（未招募）
1 期
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic LeukemiaHigh Risk Chronic Lymphocytic LeukemiaMedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2014-005530-64-HUAcerta Pharma B.V.500
招募中
3 期
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia2023-509347-27-00Acerta Pharma B.V.17